ECTE – Echo Therapeutics
SRR’s new exciting pick for the week is ECTE. Echo Therapeutics has created a unique device that may be used at home or in hospitals for diabetic patients to monitor their glucose levels. This non-invasive monitoring system is created with no needles and is also wireless. Echo Therapeutics is in the development of acquiring the FDA regulations and is on it’s way to get passed by the FDA. Once Echo Therapeutics passes FDA approval we can assure you that ECTE will be on the NASDAQ or AMEX exchange. ECTE is trading at $2.00 flat and will open tomorrow morning at that price. We suggest you take a closer look at ECTE and it’s potential before it jumps to the regulated market. http://www.echotx.com
ECTE FACTS
- They have a $15 million revenue agreement.
|
Get more ECTE info by signing up for our FREE email list















